Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

UPDATED DATA FROM ONGOING OPEN-LABEL PHASE 1B TRIAL DEMONSTRATED A MEAN 12-MONTH EGFR OF APPROXIMATELY 68 ML/MIN/1.73 M 2 POST-TRANSPLANT FOR PATIENTS ON TEGOPRUBART COMPANY ON TRACK TO REPORT TOPLINE RESULTS FROM PHASE 2 BESTOW TRIAL IN KIDNEY TRANSPLANTATION IN NOVEMBER 2025 CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $107.6 MILLION AS OF JUNE 30, 2025 IRVINE, CALIF., AUG. 14, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY REPORTED ITS SECOND QUARTER 2025 OPERATING AND FINANCIAL RESULTS AND REVIEWED RECENT BUSINESS HIGHLIGHTS.

ELEDON PHARMACEUTICALS REPORTS SECOND QUARTER 2025 OPERATING AND FINANCIAL RESULTS

DATA FROM PATIENTS WHO REMAINED ON TEGOPRUBART FOR A YEAR SHOWED OVERALL MEAN 12-MONTH EGFR OF APPROXIMATELY 68 ML/MIN/1.73 M POST-TRANSPLANT PRELIMINARY IBOX DATA, A KEY BIOMARKER OF KIDNEY FUNCTION AND IMMUNOLOGIC RESPONSE, SUPPORTS THAT TEGOPRUBART MAY IMPROVE 5-YEAR GRAFTSURVIVAL VS. CURRENT STANDARD OF CARE TEGOPRUBART CONTINUES TO BE WELL TOLERATED WITH NO CASES OF DEATH, GRAFT LOSS, DRUG RELATED TREMOR, OR NEW-ONSET DIABETES CONFERENCE CALL TO BE HELD TODAY AT 4:30 P.M.

ELEDON PRESENTS UPDATED DATA FROM ONGOING PHASE 1B TRIAL EVALUATING TEGOPRUBART FOR PREVENTION OF REJECTION IN KIDNEY TRANSPLANTATION

IRVINE, CALIF., JULY 30, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON WEDNESDAY, AUGUST 6, 2025 AT 4:30 P.M.

ELEDON PHARMACEUTICALS TO HOST A CONFERENCE CALL TO DISCUSS UPDATED DATA FROM THE ONGOING PHASE 1B TRIAL OF TEGOPRUBART IN KIDNEY TRANSPLANTATION BEING PRESENTED AT THE WORLD TRANSPLANT CONGRESS 2025

UPDATED DATA FROM ELEDON PHARMACEUTICALS' ONGOING PHASE 1B TRIAL OF TEGOPRUBART IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION TO BE PRESENTED AT WTC 2025

UPDATED DATA FROM ELEDON PHARMACEUTICALS' ONGOING PHASE 1B TRIAL OF TEGOPRUBART IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION TO BE PRESENTED AT THE WORLD TRANSPLANT CONGRESS 2025

IRVINE, CALIF., JUNE 25, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT IT WILL HOST AN R&D DAY IN NEW YORK CITY ON WEDNESDAY, JULY 9, 2025 BEGINNING AT 8:30 AM ET.

ELEDON PHARMACEUTICALS TO HOST R&D DAY ON JULY 9, 2025 IN NEW YORK CITY

ON TRACK TO REPORT TOPLINE RESULTS FROM PHASE 2 BESTOW TRIAL IN KIDNEY TRANSPLANTATION IN FOURTH QUARTER OF 2025 TEGOPRUBART USED AS A KEY COMPONENT OF IMMUNOSUPPRESSION REGIMEN IN ITS SECOND TRANSPLANT OF A GENETICALLY MODIFIED PIG KIDNEY INTO A HUMAN CONDUCTED AT MASSACHUSETTS GENERAL HOSPITAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $124.9 MILLION AS OF MARCH 31, 2025 IRVINE, CALIF., MAY 14, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY REPORTED ITS FIRST QUARTER 2025 OPERATING AND FINANCIAL RESULTS AND REVIEWED RECENT BUSINESS HIGHLIGHTS.

ELEDON PHARMACEUTICALS REPORTS FIRST QUARTER 2025 OPERATING AND FINANCIAL RESULTS

TEGOPRUBART USED AS A KEY COMPONENT OF IMMUNOSUPPRESSION REGIMEN IN THE SECOND TRANSPLANT OF A GENETICALLY MODIFIED PIG KIDNEY INTO A HUMAN CONDUCTED AT MASSACHUSETTS GENERAL HOSPITAL ANNOUNCED POSITIVE INITIAL DATA FROM FIRST THREE SUBJECTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS PART OF IMMUNOSUPPRESSION REGIMEN FOLLOWING ISLET TRANSPLANTATION IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINE TOPLINE RESULTS FROM PHASE 2 BESTOW TRIAL OF TEGOPRUBART IN KIDNEY TRANSPLANTATION EXPECTED IN FOURTH QUARTER OF 2025 PROCEEDS FROM OVERSUBSCRIBED$85 MILLIONUNDERWRITTEN OFFERING EXTEND CASH RUNWAY TO END OF 2026 IRVINE, CALIF., MARCH 20, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY REPORTED ITS FOURTH QUARTER AND FULL YEAR 2024 OPERATING AND FINANCIAL RESULTS AND REVIEWED RECENT BUSINESS HIGHLIGHTS.

ELEDON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2024 OPERATING AND FINANCIAL RESULTS

IRVINE, CALIF., MARCH 04, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT STEVE PERRIN, PH.D.

ELEDON PHARMACEUTICALS TO PARTICIPATE IN LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE

ELEDON ANNOUNCES TEGOPRUBART USE AS KEY COMPONENT OF IMMUNOSUPPRESSION REGIMEN IN ITS SECOND TRANSPLANT OF A GENETICALLY MODIFIED PIG KIDNEY INTO A HUMAN

ELEDON PHARMACEUTICALS ANNOUNCES USE OF TEGOPRUBART AS KEY COMPONENT OF IMMUNOSUPPRESSION REGIMEN IN ITS SECOND TRANSPLANT OF A GENETICALLY MODIFIED PIG KIDNEY INTO A HUMAN

IRVINE, CALIF., JAN. 29, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT DAVID-ALEXANDRE C.

ELEDON PHARMACEUTICALS TO PARTICIPATE IN GUGGENHEIM SECURITIES SMID CAP BIOTECH CONFERENCE

COMPLETED ENROLLMENT IN PHASE 2 BESTOW TRIAL ASSESSING TEGOPRUBART IN KIDNEY TRANSPLANTATION FOUR MONTHS AHEAD OF SCHEDULE; ON TRACK TO REPORT TOPLINE RESULTS IN FOURTH QUARTER OF 2025 PRESENTED UPDATED DATA ON 13 PARTICIPANTS FROM ONGOING PHASE 1B TRIAL THAT CONTINUE TO SUPPORT SAFETY AND TOLERABILITY OF TEGOPRUBART FOR PREVENTION OF ORGAN REJECTION IN KIDNEY TRANSPLANTATION ANNOUNCED POSITIVE INITIAL DATA FROM FIRST THREE SUBJECTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS PART OF IMMUNOSUPPRESSION REGIMEN FOLLOWING ISLET TRANSPLANTATION IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINE COMPLETED TWO FINANCINGS TOTALING $135 MILLION IN COMBINED GROSS PROCEEDS, WITH FUNDS EXPECTED TO SUPPORT OPERATIONS THROUGH END OF 2026 IRVINE, CALIF., JAN. 13, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED A SUMMARY OF 2024 ACCOMPLISHMENTS AND PROVIDED GUIDANCE FOR ANTICIPATED 2025 BUSINESS MILESTONES.

Eledon Pharmaceuticals, Inc.

ELDN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Eledon Pharmaceuticals, Inc.

ELDN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ELDN